LIFE SCIENCE CEO STRATEGIC GOVERNANCE FORUM

Executive Exchange and Dialogue for Small-to-Medium Life Science Enterprises, Fostering Mentorship, Collaboration and Driving Strategy for Sustainable Growth, High Level Corporate Management of Teams, Boards of Directors and Investors

Over the past 5 years, more than 450 Chief Executive Officers, Presidents and Founders from the life science industry have participated and engaged in the Q1 Life Science CEO Strategic Governance Forum, creating dialogue and synergy with like-minded executives rising to the challenge of a dynamic industry fueled by competitive growth, evolving regulatory and health policies and a changing population. Working with local industry leadership representing the most innovative and highly sought after organizations, Q1 has established a networking and discussion-based format which allows participants an opportunity to truly engage in the conversation, creating a problem solving and solution-based dialogue which has an immediate impact on corporate challenges.

BREAKOUT DISCUSSION TOPICS:

Corporate lifecycle analysis, knowledge share and collaboration on:

Capital funding

Start-Up challenges

Licensing opportunities

Technology transfer

Corporate valuation

Mergers & acquisition

Exit strategies

Addressing the rising cost of conducting business in the life sciences

Regulatory challenges in securing FDA approval for new products

Evolving reimbursement frameworks & health policy considerations

Transformation of corporate narrative to gain investor buy-in

Leadership excellence and creating an effective corporate team

Leverage of partnerships & resources to advance product development

Industry specific tracks on pricing pressure & healthcare policy

Investor relations and executive board selection & management

Funding new entities: Dilutive and non-dilutive funding & capital

Convergence of technology & healthcare: Digital health revolution

Driving corporate growth through meeting unmet medical needs

Positioning organizations for sustainable future growth & development

Development of flexible corporate architecture to allow for rapid scaling

Economic role of drugs & devices in the spectrum of healthcare delivery